Analytical Data
-
基因名
BTNL9
- Application
-
别名
rHuBTNL9, His; Butyrophilin-like protein 9; BTNL9
-
种属
Human
-
表达系统
HEK293
-
标签
C-6*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q6UXG8-1
-
表达区间
L48-S160
-
蛋白长度
Partial
-
分子量
18-30 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BTNL9 (Butyrophilin-like 9) is a member of the butyrophilin family, which plays a crucial role in the immune system by regulating T cell activation and function. The research on BTNL9 has gained traction due to its potential implications in autoimmune diseases, cancer, and infectious diseases. BTNL9 is known to interact with other immune receptors to modulate the response of T cells, particularly in the context of microbial infections and inflammatory conditions. Its unique structural features suggest that it may function as a co-inhibitory receptor, similar to its relatives, thereby influencing the balance between immune tolerance and activation. Recent studies have indicated that variations in the BTNL9 gene may be associated with susceptibility to certain diseases, prompting further investigation into its role as a biomarker and therapeutic target. The recombinant expression of BTNL9 protein has become a focal point in research, allowing scientists to delve deeper into its molecular mechanisms, interactions with T cells, and overall contributions to immune responses. This understanding could lead to novel therapeutic strategies aimed at modulating immune functions in various clinical settings, including those related to chronic inflammatory diseases and cancer immunotherapy. The ongoing exploration of BTNL9 and its recombinant protein forms holds promise for advancing our knowledge of immune regulation and developing targeted interventions in treating immune-related disorders.
